14. Heart Failure and Cardiomyopathies: Therapy 1027-03

1027-03 - EFFECT OF TREATMENT WITH DAPAGLIFLOZIN IS CONSISTENT ACROSS THE RANGE OF BODY MASS INDEX IN PATIENTS WITH HFREF: AN ANALYSIS OF THE DAPA-HF TRIAL

Session
1027 - The Buzz in SGLT2 Inhibitors and Heart Failure
Speakers
Pathway
14. Heart Failure and Cardiomyopathies: Therapy
Presentation Number
1027-03
Presentation Rating
 |